Textbook of Urgent Care Medicine, Chapter 38, Needlesticks

Original authors: Kent Erickson and John Shufeldt

Originally published in 2014. Substantially updated and clinically reviewed in 2026.

INTRODUCTION

Professionals performing direct patient care in a clinical setting may experience needlestick accidents, which are also common in many other occupations:

• Prehospital personnel and first responders
• Housekeeping personnel
• Veterinarians
• Dental professionals

Needlestick and other sharps injuries also occur among laboratory staff, students, environmental services staff, and personnel handling medical waste. The urgency of care depends on the material involved, the route and extent of exposure, and the source patient’s infection status. [1–4]

PRESENTATION

More than 30 different pathogens have been documented to cause infections secondary to needlesticks. The most important of these pathogens are human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV). Patients might also report contact with saliva or vomit, a human bite, or a splash in the eye.

An occupational exposure that warrants bloodborne-pathogen evaluation generally involves a percutaneous injury or contact of blood or other potentially infectious material with a mucous membrane or nonintact skin. Contact with intact skin alone generally does not constitute a bloodborne-pathogen exposure. [1]

TRIAGE PEARLS

Significant exposures to any of the following body fluids may present a risk of bloodborne pathogen transmission and require further evaluation:

• Blood
• Semen
• Vaginal secretions
• Cerebrospinal fluid
• Synovial fluid
• Pleural fluid
• Peritoneal fluid
• Pericardial fluid
• Amniotic fluid

Body Fluids

Substances that do not pose a significant risk of transmission unless visibly contaminated with blood include the following:

• Urine
• Saliva
• Nonpurulent sputum
• Stool
• Vomit
• Nasal discharge
• Tears
• Sweat

Interpret this distinction in the context of the pathogen and exposure route. For example, saliva in a human bite requires assessment of wound infection and tetanus risk even when it does not warrant HIV PEP. [1]

Situations Presenting a High Risk of Infection

• Exposure to a large quantity of blood or other infectious fluid
• Prolonged or extensive exposure of nonintact skin or mucous membrane to blood or other infectious fluid or concentrated virus in a laboratory setting
• Exposure to the blood of a patient with advanced disease or a high viral load
• A deep percutaneous injury
• An injury with a hollow-bore, blood-filled needle

The 2025 HIV occupational-exposure guideline advises expert consultation for a source patient with an undetectable HIV viral load, for an unknown source, or when resistance or prior HIV preexposure prophylaxis (PrEP) complicates the assessment. Neither the source’s diagnosis nor the depth of injury alone determines PEP. [1]

HISTORY PEARLS

The following information should be entered into the medical record of patients with exposure to blood:

• Name of the source if known
• Time and date of the exposure
• Tetanus status
• Dates of HBV immunization
• Postimmunization titer and date
• Nature of the exposure, including mucous membrane versus intact or nonintact skin, type of secretion (blood, saliva, etc.), and inciting event (needlestick with a hollow or solid needle)
• Body location of the exposure and the contact time with the contaminated substance
• Infective status of the source (i.e., HIV, HCV, hepatitis B surface antigen [HBsAg])
• Date of last testing for disease state

Record whether the needle was used intravascularly, whether visible blood was present, whether the source patient can be tested, and whether the exposed person is pregnant, breastfeeding, receiving PrEP, or taking medications that may interact with HIV PEP. Document HBV vaccine records and any prior quantitative anti-HBs result. [1,2]

PHYSICAL EXAM PEARLS

Of particular importance are the nature and degree of wound contamination. General guidelines for describing the injury are as follows:

• Body location of the exposure and contact time with the contaminated fluid
• Degree of wound contamination
• Description of the injury if it is percutaneous (depth of wound, solid versus hollow needle, sharp use in source patient)

Depending on the exposure site, the following treatments should be provided:

• Irrigate area and clean with soap and water
• Irrigate mucous membranes with water
• Irrigate eyes with saline solution

Do not use or inject antiseptics on or into the wound.

Do not squeeze, cut, or deliberately bleed the puncture site. Remove contaminated clothing, assess for concurrent injuries, and report a potentially infectious exposure promptly. First aid and diagnostic sampling must not delay HIV PEP when it is indicated. [1]

TESTING AND DIAGNOSIS PEARLS

Evaluation of the Exposure Source

When the source patient is known, obtain consent and perform testing consistent with local law, institutional policy, and the urgency of the exposure. Use a rapid or laboratory fourth-generation HIV antigen/antibody assay; do not rely on an obsolete Western blot confirmation pathway. Assess HBV with source HBsAg and HCV preferably with HCV RNA, or HCV antibody with reflex RNA if positive. Obtain testing as promptly as feasible, preferably within 48 hours for HCV. [1–3]

Do not delay administration of HIV PEP while waiting for information regarding the source patient’s HIV status. If the source is confirmed HIV negative, HIV PEP and related follow-up can generally be stopped. If an acute HIV infection in the source is suspected despite a negative initial screening test, consult an expert regarding HIV RNA testing. [1]

State regulations related to informed consent and confidentiality should be followed.

When the source patient is not known, evaluate the likelihood of high-risk exposure.

• Consider the likelihood of bloodborne pathogen infection among patients in the exposure setting; do not assume a discarded needle is infectious.
• Do not test the discarded needle or other sharp itself for HIV.
• Make a time-sensitive, individualized HIV PEP decision with an expert when the source is unknown; do not treat the obsolete low-risk/high-risk two-drug rules as a decision algorithm.

Testing the Exposed Patient

Obtain baseline fourth-generation HIV antigen/antibody testing and, when HIV PEP is prescribed, serum creatinine, AST, and ALT. Follow the 2025 PHS recommendations for any additional baseline HIV RNA testing, particularly after recent long-acting cabotegravir PrEP. Baseline results document preexposure status but must not delay indicated PEP. [1]

For HCV, obtain baseline anti-HCV with reflex HCV RNA if positive, preferably within 48 hours. For HBV, test anti-HBs when required by vaccination history and source status. Persons susceptible to HBV exposed to an HBsAg-positive or unknown-status source also require baseline total anti-HBc and follow-up infection testing. [2–4]

Disease-Specific Risk

• HBV transmission risk is strongly modified by the source patient’s infection status and the exposed person’s documented vaccine response. An anti-HBs concentration of at least 10 mIU/mL after a completed vaccine series indicates protection for immunocompetent healthcare personnel. [2,3]
• HCV transmission after an occupational percutaneous exposure is uncommon; CDC estimates approximately 0.2% risk in contemporary surveillance data. The absence of an effective HCV vaccine or recommended HCV PEP makes timely RNA follow-up especially important. [4]
• HIV risk varies by route, inoculum, and source characteristics. Decisions about PEP should be individualized and made without waiting for every laboratory result; the 2025 guideline also addresses source patients with undetectable viral loads. [1]

MANAGEMENT PEARLS

Postexposure Prophylaxis for Hepatitis B Virus Exposure

The response depends on the vaccination and antibody status of the exposed healthcare worker and the source patient’s HBsAg status. Give HBV immune globulin (HBIG) and indicated vaccine doses as soon as possible when required; do not delay while arranging occupational-health follow-up. HBIG is administered intramuscularly at 0.06 mL/kg. [2,3]

Adapted from the CDC healthcare-setting HBV postexposure guidance (2024). Anti-HBs is antibody to hepatitis B surface antigen; HBsAg is hepatitis B surface antigen; HBIG is hepatitis B immune globulin. Consult the full guidance for vaccine schedules, HBIG timing, and follow-up testing. [2,3]

Postexposure Prophylaxis for Hepatitis C Virus Exposure

Immunoglobulin is not effective.

There is no recommended HCV postexposure medication. Do not administer interferon or direct-acting antivirals empirically as routine HCV PEP. Test the exposed person as indicated and refer promptly for curative direct-acting antiviral treatment if HCV RNA becomes detectable. [4]

Postexposure Prophylaxis for Human Immunodeficiency Virus Exposure

Continue PEP for 28 days.

Start HIV PEP as soon as possible after a substantial exposure, ideally within hours and up to 72 hours. For an exposure presenting substantial risk more than 72 hours earlier, discuss the circumstances urgently with an HIV expert. Do not withhold initial PEP while source tests or expert consultation are pending. [1]

For most adults without contraindications, the 2025 PHS guideline lists bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) once daily or dolutegravir plus tenofovir (alafenamide or disoproxil fumarate) plus emtricitabine or lamivudine as preferred three-drug PEP options. Selection, dosing, drug interactions, renal and hepatic impairment, pregnancy, and PrEP use require regimen-specific review and sometimes expert consultation. [1]

The 2014 risk-based two-drug regimens containing zidovudine/lamivudine and the older lopinavir/ritonavir schedules have been removed. They do not represent preferred 2026 occupational HIV PEP. [1]

Algorithm replaces the source chapter’s 2014 two-drug/three-drug HIV PEP flowchart. Use the linked national guidance and local occupational exposure protocol for patient-specific decisions. [1–4]

Disease-Specific Follow-Up

• HBV: Exposed personnel lacking documented protection and exposed to HBsAg-positive or unknown-status sources should have baseline total anti-HBc and follow-up HBsAg plus total anti-HBc at approximately 6 months. Verify vaccine response (anti-HBs) 1–2 months after the final vaccine dose, allowing additional time after HBIG. [2,3]
• HCV: When the source has detectable HCV RNA, positive HCV antibody with unknown RNA, or cannot be tested, obtain exposed-person HCV RNA at 3–6 weeks. If negative, repeat anti-HCV with reflex RNA at 4–6 months; if anti-HCV was already positive at baseline with RNA negative, use RNA for follow-up. [4]
• HIV: Re-evaluate the exposed person within 72 hours of exposure. Perform final laboratory HIV fourth-generation Ag/Ab plus HIV NAT at 12 weeks; add interim Ag/Ab plus NAT at 4–6 weeks when PEP began more than 24 hours after a single exposure or doses were missed. Additional renal or hepatic toxicity tests are not routinely needed unless baseline results or symptoms warrant them. [1]
• Provide counseling regarding PEP adherence, possible medication interactions, acute illness, barrier precautions, and avoidance of blood and tissue donation until the final testing interval. Document a named clinician or service responsible for obtaining results and ensuring follow-up. [1]

CARE ALGORITHM

The original 2014 graphic stratified HIV PEP into two-drug and three-drug regimens according to source category. The modern care algorithm is presented in Table 2 and should be read with the disease-specific sections above. An unknown source requires individualized assessment rather than automatic classification as low risk. [1]

The National Clinician Consultation Center provides specialist consultation on HIV and viral hepatitis postexposure management: https://nccc.ucsf.edu/clinician-consultation/ . Its current consultation contact and hours should be checked directly rather than relying on the 2014 telephone listing. [5]

MEDICOLEGAL PEARLS

• Obtain patients’ informed consent about their options for testing and treatment.
• Do not disclose protected health information unless the patient has consented.
• Know the state statutes regarding what must be reported.

Document the counseling and PEP discussion, first-dose timing when applicable, source-testing authorization, vaccine records, the designated follow-up clinician, and any reasons for declining prophylaxis. Follow state reporting and confidentiality requirements, occupational health protocols, and workplace injury procedures. [1–3]

References

1. Kofman AD, Struble KA, Heneine W, et al. 2025 US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for post-exposure prophylaxis in healthcare settings. Infect Control Hosp Epidemiol. 2025;46(9):863-873. doi:10.1017/ice.2025.10254 Source
2. Centers for Disease Control and Prevention. Responding to HBV exposures in health care settings. Updated May 16, 2024. Source
3. Centers for Disease Control and Prevention. Table 1: Treatment for HBV exposures in health care settings. Updated May 13, 2024. Source
4. Moorman AC, de Perio MA, Goldschmidt R, et al. Testing and clinical management of health care personnel potentially exposed to hepatitis C virus—CDC guidance, United States, 2020. MMWR Recomm Rep. 2020;69(6):1-8. doi:10.15585/mmwr.rr6906a1 Source
5. National Clinician Consultation Center. Clinician consultation resources. University of California, San Francisco. Accessed October 30, 2026. Source